NCT00953862View on ClinicalTrials.gov

Atomoxetine/Attention Deficit/ Hyperactive Disorder (ADHD)/Substance Use Disorder (SUD)in a Residential Treatment Facility

NACompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

July 31, 2005

Primary Completion Date

April 30, 2008

Study Completion Date

April 30, 2008

Conditions
Attention Deficit Hyperactivity Disorder
Interventions
DRUG

Atomoxetine

In Phase II, atomoxetine was dispensed beginning at 25 mg/day. Dose was adjusted based on clinical response and tolerability over a 4-week period up to 120mg/day and held constant at the optimized level for the final 6 weeks of the trial.

All Listed Sponsors
collaborator

Eli Lilly and Company

INDUSTRY

lead

NYU Langone Health

OTHER

NCT00953862 - Atomoxetine/Attention Deficit/ Hyperactive Disorder (ADHD)/Substance Use Disorder (SUD)in a Residential Treatment Facility | Biotech Hunter | Biotech Hunter